StemCell Therapy

Two recent studies by a UB researcher could help increase safety and minimize expense for patients undergoing glaucoma surgery.

The studies were conducted over several years by Asher Weiner, clinical associate professor in the Department of Ophthalmology in the Jacobs School of Medicine and Biomedical Sciences at UB. Weiner is affiliated with UBMD Ophthalmology at the Ross Eye Institute.

Glaucoma is one of the leading causes of blindness in people over the age of 60. It is a progressive condition in which the optic nerve, which is vital for vision, is damaged, often by abnormally high pressure in the eye (intraocular pressure, or IOP). This high pressure occurs when there is a buildup of fluid (aqueous humor) inside the eye, and in order to prevent blindness from glaucoma, IOP must be reduced to a safe level.

The first study was published in the Journal of Glaucoma in May. This retrospective, interventional research was conducted in a private glaucoma and cataract practice in Albany, New York, between 2014 and 2016. Weiner was affiliated with St. Peters Hospital in Albany at that time. He moved to Buffalo in 2017.

In this study, researchers sought to compare the safety and success rate of two different types of minimally invasive glaucoma surgery, or MIGS.

Instead of creating or implanting artificial drainage systems into the eye to reduce IOP procedures with increased intra- and postoperative risk most MIGS procedures utilize and enhance the eyes natural drainage system, increasing the drainage out of the eye and thereby reducing IOP.

The eyes drainage system is naturally restricted by the trabecular meshwork, the so-called strainer in the sink, Weiner says. Most MIGS procedures either remove a significant portion of this natural barrier, or bypass it using a tiny stent.

Weiner conducted the first MIGS in Michigan 12 years ago. Since then, as the success of MIGS has been demonstrated and confirmed, manufacturers have begun to develop devices to insert through the trabecular meshwork to achieve better flow out of the natural drain. There is a significant cost difference among different types of MIGS, ranging from $300-$650 with no implanted stent, to $1,750 with a stent.

In this study, Weiner compared two different types of MIGS with and without a stent over several years to also determine if the extra cost is justified for the patient and to the health care system.

He compared the surgical outcomes in patients who had two different types of MIGS in their eyes one that included implanting a stent in one eye, and one without a stent in the other eye. The objective, he says, was to examine whether the outcomes are the same, and whether a higher expense is justified.

The research found that the original method, without implanting the stent, does a better job than the stent, he says.

The bottom line is that the expensive device was less effective than the more economical original method, he says.

The second study was published online ahead of print in July in the journal Ophthalmology Glaucoma. Like the earlier research, it was a retrospective, interventional study conducted in Weiners Albany private practice between 2014 and 2016.

When lower-risk surgeries such as MIGS are insufficient to protect the optic nerve from progressive glaucoma damage, tube shunt implantation is a more effective method to reduce intraocular pressure to a safer level. However, this more aggressive procedure could increase intra- and postoperative risks.

According to the American Academy of Ophthalmology, the principal postoperative risk following tube shunt implantation into the anterior chamber of the eye (the location in the eye where tubes have traditionally been placed) is corneal decompensation and failure, leading to loss of vision and a need for corneal transplantation in an attempt to restore vision.

Thus, Weiner explains, the drawback to implanting tubes into the anterior chamber of the eye is that the tube is placed too close to the cornea, leading to corneal endothelial cell damage and corneal failure over time.

The alternative method is to insert the tube shunt behind the iris through an area called the ciliary sulcus instead of into the anterior chamber, thereby hiding the tubes behind the iris far enough from the cornea to prevent corneal damage and long-term visual loss.

Weiner has been working to further develop this surgical method for the past 12 years, and has presented his results through multiple publications and presentations.

In this study, the authors compared the rate of decline in corneal endothelial cell density following sulcus tube shunt implantation. The research showed that the rate of cell loss following sulcus tubes was a non-statistically significant 8% over two years, compared to a statistically significant loss of 20% to 30% following tubes implanted into the anterior chamber.

There was still loss, but not as dire when the tube shunt was inserted through the sulcus, and none of our patients demonstrated clinical corneal damage, Weiner says. This was the first time this was demonstrated.

The researchers also measured cell loss in eyes with glaucoma that were not being treated with shunts. Those eyes also showed cell loss (3%) over the two-year period, Weiner says.

Our findings strengthen the argument for how tube shunts should be implanted to protect our patients long-term vision, he says. But since our surgical methods require a higher skill level and may require a slightly longer operative time, many surgeons still prefer the old method.

However, in recent years, researchers have seen greater conversion to sulcus tubes around the world, he adds.

Co-authors on both studies include Weiners sons, Adam J. Weiner and Yotam Weiner from Beaumont Hospital, Oakland University William Beaumont School of Medicine in Royal Oak, Michigan.

Read the rest here:
Comparisons of glaucoma surgeries show certain techniques are safer, more effective - UB Now: News and views for UB faculty and staff - University at...

The Food and Drug Administration continues to add hand sanitizers to a list of products that should be avoided, with the list climbing to 196.

Many of the recalled products contain methanol or 1-propanol, which are very dangerous. Only ethyl alcohol and isopropyl alcohol (also known as 2-propanol) are acceptable types of alcohol in hand sanitizer, according to the FDA.

The complete list can befound on the FDAs site.

FDA test results also showed some hand sanitizers had much lower levels of active ingredient than listed on the label. The CDC recommends alcohol-based hand sanitizers have at least 60% ethyl alcohol (sometimes listed as alcohol on the label).

Other products were found with false or misleading claims on labels, including false claims that the brand prevents the spread of COVID-19 or protects you from viruses or bacteria for a certain period of time.

Methanol, or methyl alcohol, is used to make rocket fuel and antifreeze and should never be rubbed on your skin or swallowed. Swallowing or drinking hand sanitizers contaminated with methanol can cause serious health problems, including permanent blindness, and death, according to the FDA.

1-Propanol or 1-propyl alcohol is used to make industrial solvents and can also be toxic when swallowed. Swallowing or drinking a hand sanitizer with 1-propanol can result in decreased breathing and heart rate, among other serious symptoms, and can lead to death, the FDA says.Symptoms of exposure can include confusion, decreased consciousness and slowed pulse and breathing.

The FDA also says hand sanitizer should never be used on pets. If your pet gets hand sanitizer on their skin or accidentally ingests it (such as by chewing the bottle), the FDA says to contact your veterinarian or an animal poison control service immediately.

Read this article:
More products added to FDA hand sanitizer recall list - FOX40

Angela Elam

(PRESS RELEASE) CHICAGO Fight for Sight, the first nonprofit organization in the United States to promote eye research, and Prevent Blindness, the nations oldest voluntary eye health organization, announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elams study, Engagement in Telemedicine-based Glaucoma Screening in the Community Clinics.

The Joanne Angle Public Health Award is presented annually to research focusing on the public health side of vision and eye health. It was named for Ms. Joanne Angle who served on the National Board of Directors for Prevent Blindness, and both its Government Affairs and Audit committees, in addition to her work with the Association for Research in Vision and Ophthalmology (ARVO). Glaucoma is a group of eye conditions that damage the optic nerve, often caused by an abnormally high pressure in the eye. Those with glaucoma usually start losing their side (peripheral) vision. According to the Prevent Blindness report, The Future of Vision: Forecasting the Prevalence and Costs of Vision Problems, there are more than 3.2 million older adults in America with glaucoma. The total number is expected to increase rapidly as the U.S. population ages. Minority populations will also increasingly be affected.

The purpose of the Engagement in Telemedicine-based Glaucoma Screening in the Community Clinics study is to identify innovative strategies to better engage populations of people most at risk of vision loss from glaucoma and who are least likely to have access to an eye care provider in glaucoma screening and treatment. Both poverty and being of minority background lead to a higher risk of having glaucoma, and not getting adequate specialty treatment for glaucoma.

Dr. Elam is leading her team in implementing a telemedicine-based glaucoma screening program in two free clinics to overcome many of the logistical and psychosocial barriers to glaucoma screening. Interviews will be conducted of clinic staff, patients, and those accessing non-medical services to identify the best ways to engage community participants in the glaucoma screening program.

Telemedicine is truly making a tremendous impact in providing essential services to those who do not have the access they need to stay healthy, said Jeff Todd, president and CEO of Prevent Blindness. We are proud to give Dr. Angela Elam and her team this years Joanne Angle Public Health Award that provides funding that helps to save sight in those at highest risk for vision loss from glaucoma.

Fight for Sight is glad to partner with Prevent Blindness and congratulates Dr. Elam and her team on this award, said Michael Brogioli, executive director of Fight for Sight. Their work to engage underserved communities is especially critical during this extraordinary time.

Past recipients of the Prevent Blindness Joanne Angle Award include Brian J. Song, MD, MPH, at the Massachusetts Eye and Ear, and the Department of Ophthalmology at Harvard Medical School, for his study Glaucoma Detection in Diabetes Teleretinal Programs, and Rajeev S. Ramchandran, MD, MBA, Associate Professor of Ophthalmology, University of Rochester School of Medicine and Dentistry, for his study, Implementation Science Based Study of Teleophthalmology for Diabetic Retinopathy Surveillance.

For more information on the Fight for Sight-Prevent Blindness Joanne Angle Public Health Award, please contact Jean Song, Fight for Sight, at [emailprotected].

Read more here:
Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Award - InvisionMag

Why Global Citizens Should Care

When William Tasiame saw a young boy infected with rabies, he knew the child was going to die.

"He gasped for breath, hiding his face from the light. I knew the symptoms from dogs, they are similar. It is a sad death and it was the worst thing I have seen in my life," Tasiame told Global Citizen.

Tasiame studied veterinary medicine in Cuba, before going back to his home country of Ghana, where he worked as a veterinarian for 12 years. Today, he is doing research for his doctoral thesis on rabies under Christian Drosten at the Charit in Berlin, Germany.

Although rabies had always been an interest in Tasiames professional life, it wasnt until he saw that child suffering from it with his own eyes that he decided he would dedicate his research and all his energy to fighting it.

Once a person begins to show signs of having rabies, it will almost always lead to death. Signs and symptoms include headaches, nausea, vomiting, abdominal pain, diarrhea, fever, or cough. But they also include confusion, difficulty swallowing, hallucinations, and a fear of water, according to the Centers for Disease Control and Prevention (CDC).

Rabies is almost always transmitted by infected animals, mostly dogs or wild animals, such as foxes, bats, and raccoons. The virus travels through the nerves to the spinal cord and brain. It usually takes three to eight weeks between initial contact with the virus and the onset of symptoms.

"Rabies is a very brutal disease that mainly affects children and there is nothing you can do about it. There are no active ingredients or medication to combat it. Once the brain is affected, it's too late," Tabea Binger, laboratory manager of the Kumasi Center for Collaborative Research, a research facility of the Bernhard Nocht Institute for Tropical Medicine in Ghana, told Global Citizen.

Like Tasiame, Binger also wrote her doctoral thesis under Christian Drosten. She focused on viruses that infect bats and that can be transmitted to humans one of which is the rabies virus.

Having studied the virus so intensively, Binger explained that she has been vaccinated against rabies and that every year, she was tested to ensure that the protection provided by the vaccine was still sufficient.

"Most people do not have this luxury, she said. But they actually need this vaccination urgently.

Rabies is one of the diseases on the World Health Organizations (WHO) list of NTDs. These diseases are most common in tropical regions, where access to health care or water and sanitation is often poor in global comparison.

There are solutions to some of these diseases readily available, but NTDs are not prioritized globally. And while some pharmaceutical companies have donated treatments and worked to tackle these diseases, there is minimal research and development being conducted on NTDs as there is no market for the drugs.

There is no effective drug against rabies. There is a vaccine, but it requires three doses per person, which can be difficult to deliver in areas with little access to health care.

Related Stories

More than 59,000 people die every year worldwide from this NTD, with 95% of human cases occurring in Africa and Asia, according to the WHO.

"With the polio [vaccine], it is only three drops to swallow. Here in Ghana, polio workers go from door to door to distribute the vaccine to every child under 5 years of age. I have a little daughter who has just had this done,"Binger explained. "But, unfortunately, there is no such simple vaccine against rabies for humans."

What makes it all the more tragic is that more than 40% of the rabies cases affect children under 15 and most of them are caused by a dog bite, Tasiame added.

Diagnosing rabies is also a challenge as there are no efficient or cost-effective rapid tests available. This means that doctors have to find alternative methods to confirm if a child has been bitten and infected by an animal.

"Children often say that they didn't tease the dog so that they don't get into trouble it just happened that he bit out of the blue. But that makes it difficult for us to find out whether the dog had rabies or not," Tasiame said. "The only thing us vets can do is go to the village and find the dog then I can know for certain whether it was a sick dog or not."

Theoretically, it is possible to administer a post-bite vaccine to prevent death from rabies.

"This does not work very well in Ghana. As a doctor, you have to know that the patient actually has rabies. You have to be able to obtain the vaccine because it is usually only available in the capital, Accra, but the cases occur far away, in the very north of Ghana, more than 13 hours by car," Binger said.

It is also impossible to vaccinate all children that have received a dog bite as the vaccine is far too expensive.

That is why attempts are being made to instead vaccinate the disease vectors in Ghana, this generally means dogs.

Related Stories

"The primary solution to rabies is to vaccinate as many dogs as possible,"Tasiame said.

The vaccine for dogs costs about $1.75 per vaccination, which is significantly cheaper than the one for humans, which costs around $105.

"In Ghana, the method is particularly useful because there are hardly any street dogs here every dog has an owner. We just have to get hold of the dogs and raise enough money to vaccinate enough dogs,:Tasiame said.

The government of Ghana has not done much to address this health crisis, according to Tasiame. The vet says that the last government-initiated vaccination campaign against rabies in Ghana took place in the 1970s.

Last year, Tasiame launched a vaccination campaign to educate about the disease and vaccinate dogs free of charge.

"The people who are most exposed to rabies infection are poor people. The area where I started the campaign is in the north of Ghana, a poor area. I went there for the first time last year. It feels like driving to the end of the world. The roads are bad, water and electricity supplies, and health care are a problem," Tasiame said. "Last year, we vaccinated 650 dogs, but that is not enough. Statistics show that we have 1.4 million dogs in Ghana."

About 70% of the dogs would have to be vaccinated to provide sufficient protection and this would need to be done every year.

Related Stories

"This year, we have collected enough money to vaccinate about 1,000 dogs most of it comes from friends," Tasiame said, adding that him and his team have also launched a small appeal and set up a function that allows people to donate via SMS.

Through word of mouth, Tasiame and his team encourage dog owners to bring their dogs for vaccination on World Rabies Day. The campaign takes place in a well-known place in the village so that its easy for everyone to find.

Tasiame's wish is for the world to see the issue and take action on it.

"Most people who die of rabies live in rural areas they have no education, no water, no road network,"he said. "And they still have to die of a disease that could be prevented with vaccines. That hurts me the most."

Go here to read the rest:
This Preventable Disease Kills Tens of Thousands of Children Every Year - globalcitizen.org

Watch here: https://www.youtube.com/watch?feature=youtu.be&v=VVkQU91KbEs

press release: The UW has a long history of pioneering medical advancements that have transformed the world. From performing the first bone marrow transplant in the United States to cultivating the first laboratory-derived human embryonic stem cells. Now, where will UW medical research go next?

On the next Wisconsin Medicine Livestream, meet trailblazing doctors, researchers, and medical leaders who are charting a bold course to completely alter the health care landscape. During this insightful panel discussion, well explore how gene therapy and cell replacements could hold the keys to treating inherited and acquired blindness. Youll also discover the remarkable potential in xenotransplantation where nonhuman animal source organs are transplanted into human recipients. In addition, you will learn about UW Healths journey to build a multidisciplinary program to serve the community. These, and other, fascinating developments in treatment and care are happening right now at the UW and are the future of medicine. The presentation will be moderated by Robert Golden, the dean of the University of WisconsinMadisons School of Medicine and Public Health.

Our Guests:

David Gamm, professor, Department of Ophthalmology and Visual Sciences; Emmett A. Humble Distinguished Director, McPherson Eye Research Institute; Sandra Lemke Trout Chair in Eye Research

Dr. Gamms lab is at the forefront in developing cell-based therapies to combat retinal degenerative diseases (RDDs). As the director of the McPherson Eye Research Institute and a member of the Waisman Center Stem Cell Research Program, the UW Stem Cell and Regenerative Medicine Center, and the American Society for Clinical Investigation, his efforts are directed toward basic and translational retinal stem cell research. The Gamm Lab uses induced pluripotent stem cells to create retinal tissues composed of authentic human photoreceptor cells rods and cones that can detect light and initiate visual signals in a dish. The aims of his laboratory are to investigate the cellular and molecular events that occur during human retinal development and to generate cells for use in retinal disease modeling and cell replacement therapies. In collaboration with other researchers at UWMadison and around the world, the lab is developing methods to produce and transplant photoreceptors and/or retinal pigment epithelium (RPE) in preparation for future clinical trials. At the same time, the Gamm Lab uses lab-grown photoreceptor and RPE cells to test and advance a host of other experimental treatments, including gene therapies. In so doing, the lab seeks to delay or reverse the effects of blinding disorders, such as retinitis pigmentosa and age-related macular degeneration, and to develop or codevelop effective interventions for these RDDs at all stages of disease.

Dhanansayan Shanmuganayagam, assistant professor, Department of Surgery, School of Medicine and Public Health; Department of Animal and Dairy Sciences, UWMadison; director, Biomedical, and Genomic Research Group

Dr. Shanmuganayagams research focuses on the development and utilization of pigs as homologous models to close the translational gap in human disease research, taking advantage of the overwhelming similarities between pigs and humans in terms of genetics, anatomy, physiology, and immunology. He and his colleagues created the human-sized Wisconsin Miniature Swine breed that is unique to the university. The breed exhibits greater physiological similarity to humans, particularly in vascular biology and in modeling metabolic disorders and obesity. He currently leads genetic engineering of swine at the UW. His team has created more than 15 genetic porcine models including several of pediatric genetic cancer-predisposition disorders such as neurofibromatosis type 1 (NF1). In the context of NF1, his lab is studying the role of alternative splicing of the nf1 gene on the tissue-specific function of neurofibromin and whether gene therapy to modulate the regulation of this splicing can be used as a viable treatment strategy for children with the disorder.

Dr. Shanmuganayagam is also currently leading the efforts to establish the University of Wisconsin Center for Biomedical Swine Research and Innovation (CBSRI) that will leverage the translatability of research in pig models and UWMadisons unique swine and biomedical research infrastructure, resources, and expertise to conduct innovative basic and translational research on human diseases. The central mission of CBSRI is to innovate and accelerate the discovery and development of clinically relevant therapies and technologies. The center will also serve to innovate graduate and medical training. As the only center of its kind in the United States, CBSRI will make UWMadison a hub of translational research and industry-partnered biomedical innovation.

Petros Anagnostopoulos, surgeon in chief, American Family Childrens Hospital; chief, Section of Pediatric Cardiothoracic Surgery; professor, Department of Surgery, Division of Cardiothoracic Surgery

Dr. Anagnostopoulos is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He completed two fellowships, one in cardiothoracic surgery at the University of Pittsburgh School of Medicine and a second in pediatric cardiac surgery at the University of California, San Francisco School of Medicine. He completed his general surgery residency at Henry Ford Hospital in Detroit. Dr. Anagnostopoulos received his MD from the University of Athens Medical School, Greece. His clinical interests include pediatric congenital heart surgery and minimally invasive heart surgery.

Dr. Anagnostopoulos specializes in complex neonatal and infant cardiac reconstructive surgery, pediatric heart surgery, adult congenital cardiac surgery, single ventricle palliation, extracorporeal life support, extracorporeal membrane oxygenation, ventricular assist devices, minimally invasive cardiac surgery, hybrid surgical-catheterization cardiac surgery, off-pump cardiac surgery, complex mitral and tricuspid valve repair, aortic root surgery, tetralogy of Fallot, coronary artery anomalies, Ross operations, obstructive cardiomyopathy, and heart transplantation.

When: Tuesday, Sept. 29, at 7 p.m. CDT

Where: Wisconsin Medicine Livestream: wiscmedicine.org/programs/ending-alzheimers

See the original post:
ONLINE: The Future of Medicine - Isthmus

While vitamin A is available in everything from meat and fish to colorful fruits and vegetables, there is still a risk of deficiency. Thankfully, changes to your diet and supplement use can help ensure your vitamin A levels are sufficient and stable.

Here's how to recognize the symptoms and signs of vitamin A deficiency and what you can do to treat it.

Vitamin A is a fat-soluble vitamin stored in the liver and fat tissues. It is important for a variety of bodily functions, but especially for cell differentiation. Cell differentiation occurs in adults whenever tissue renews itself either from damage or disease. It is the process by which cells become specific to parts of the body, such as brain cells, eyes cells, and skin cells, says Ashley Reaver, MS, RD, CSSD.

Due to Vitamin A's role in cell differentiation, it's important for repairing skin and maintaining eye health. Vitamin A also acts as an antioxidant, helping to reduce inflammation and supporting immune system response, says Bansari Acharya, RDN, a registered dietitian-nutritionist in Detroit, Michigan.

Learn more about the health benefits of vitamin A and how antioxidants work.

The first symptom of a vitamin A deficiency is night blindness, a condition in which people lose the ability to see in the dark, says Reaver. That's because vitamin A helps develop the molecules that help you see color that are also required for night vision.

If vitamin A deficiency is left untreated, the temporary night vision can develop into a condition known as xerophthalmia. Xerophthalmia is an umbrella term used for signs of a vitamin A deficiency in the eyes, such as corneal xerosis when the cornea appears dry and hazy. Xerophthalmia is one of the leading causes of preventable blindness worldwide, says Reaver.

Night blindness can be reversed by consuming adequate amounts of vitamin A, says Reaver. However, once a person's vision progresses to complete blindness, changing their vitamin A intake is not adequate enough to restore their sight.

Other signs of vitamin A deficiency include:

When a person does not meet their daily recommended intake of vitamin A, they become deficient. The amount of vitamin A needed varies by gender and age.

It is rare for people living in developed countries to have a vitamin A deficiency. For instance, in the United States, less than 1% of people are vitamin A deficient.

The condition is more prevalent in food-insecure countries where people don't have access to either a variety of healthy foods, an adequate amount of food, or both.

According to Reaver, the risk of becoming vitamin A deficient is especially high for the following individuals in food-insecure countries:

Vitamin A deficiency can occur in infants who are not regularly consuming enough breastmilk or formula. It can also occur in developing countries where chronic diarrhea is common in children, says Acharya.

In more developed countries, Reaver says those who are at risk for developing a vitamin A deficiency include:

These conditions can lead to a vitamin A deficiency due to malnourishment, lower intake of the nutrient, or issues with absorbing fat.

If you believe you have a vitamin A deficiency, visit a doctor as soon as possible to receive an accurate diagnosis.

Your doctor will order a blood test to determine the amount of vitamin A in your blood. Normal vitamin A ranges from 15 to 60 mcg/dL (micrograms per deciliter), so anything below 15 mcg/dL is considered deficient.

Acting swiftly can prevent long-term consequences like blindness from developing.

Vitamin A deficiency can be treated in two ways, says Reaver:

Adding vitamin A into your diet is often the first course of action, but supplements may be necessary depending on the severity of an individual's symptoms, Acharya says. How much vitamin A you need from supplementation depends on age:

Foods high in vitamin A include:

Yuqing Liu/Insider

Vitamin A deficiency is uncommon in developed countries like the United States.

People, especially children, and pregnant women, who live in countries that lack access to adequate amounts of healthy foods and clean water are at a higher risk of becoming vitamin A deficient.

Signs of deficiency include night blindness and rashes. Vitamin A deficiency can be treated through supplementation or increasing the amount of vitamin A-rich foods you eat.

See the original post here:
Signs and symptoms of vitamin A deficiency and how to treat it - Insider - INSIDER

News Release

Monday, September 28, 2020

NIH-funded study points to genes that control the establishment of neural circuits during early development.

In an article published in Nature Genetics, researchers confirm that about 14% of all cases of cerebral palsy, a disabling brain disorder for which there are no cures, may be linked to a patients genes and suggest that many of those genes control how brain circuits become wired during early development. This conclusion is based on the largest genetic study of cerebral palsy ever conducted. The results led to recommended changes in the treatment of at least three patients, highlighting the importance of understanding the role genes play in the disorder. The work was largely funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

Our results provide the strongest evidence to date that a significant portion of cerebral palsy cases can be linked to rare genetic mutations, and in doing so identified several key genetic pathways involved, said Michael Kruer, M.D., a neurogeneticist at Phoenix Childrens Hospital and the University of Arizona College of Medicine - Phoenix and a senior author of the article. We hope this will give patients living with cerebral palsy and their loved ones a better understanding of the disorder and doctors a clearer roadmap for diagnosing and treating them.

Cerebral palsy affects approximately one in 323 children in the United States. Signs of the disorder appear early in childhood resulting in a wide range of permanently disabling problems with movement and posture, including spasticity, muscle weakness, and abnormal gait. Nearly 40% of patients need some assistance with walking. In addition, many patients may also suffer epileptic seizures, blindness, hearing and speech problems, scoliosis, and intellectual disabilities.

Since its first official description in 1862, scientists have hotly debated whether cerebral palsy is caused by problems at birth. For instance, it is known that babies born prematurely or who experience a lack of blood flow or oxygen during birth have a greater chance of suffering from the disorder. Later though, researchers concluded that a majority (85-90%) of all cases are congenital, or born with the disease, and some studies had suggested that cerebral palsy could be inherited. Despite this, the causes of many childrens cases had remained elusive.

Then in 2004, scientists discovered the first genetic mutation known to cause cerebral palsy. Since then several more mutations have been identified and depending on how an experiment was performed, scientists have estimated that anywhere from 2 to 30% of all cases may be linked to a misspelling in a patients DNA. In this study, the researchers provided support for a previous estimate and highlighted which genes may play a critical role in the disorder.

Cerebral palsy is one of neurologys oldest unresolved mysteries. The results from this study show how advances in genomic research provide scientists with the hard evidence they need to unravel the causes behind this and other debilitating neurological disorders, said Jim Koenig, Ph.D., program director at NINDS.

The study was led by Sheng Chih (Peter) Jin, Ph.D., assistant professor of genetics at Washington University School of Medicine, St. Louis, and Sara A. Lewis, Ph.D., a post-doc in the lab Dr. Kruer leads.

The researchers searched for what are known as de novo, or spontaneous, mutations in the genes of 250 families from the United States, China, and Australia through a collaboration made possible by the International Cerebral Palsy Genomics Consortium. These rare mutations are thought to happen when cells accidentally make mistakes copying their DNA as they multiply and divide. An advanced technique, called whole exome sequencing, was used to read out and compare the exact codes of each gene inscribed in the chromosomes of the patients with that of their parents. Any new differences represented de novo mutations that either happened while a parents sperm or egg cell multiplied or after conception.

Initially the researchers found that the cerebral palsy patients had higher levels of potentially harmful de novo mutations than their parents. Many of these mutations appeared to be concentrated in genes that are highly sensitive to the slightest changes in the DNA letter code. In fact, they estimated that about 11.9% of the cases could be explained by damaging de novo mutations. This was especially true for the idiopathic cases which had no known cause and represented the majority (62.8%) of cases in the study.

Approximately another 2% of the cases appeared to be linked to recessive, or weaker, versions of genes. This raised the estimate of cases that could be linked to genetic problems from 11.9% to 14%, as has been previously reported.

Moreover, the results led to recommendations for more tailored treatments of three patients.

The hope of human genome research is that it will help doctors find the best, most personalized, matches between treatments and diseases. These results suggest that this may be possible for some patients with cerebral palsy, said Chris Wellington, program director in the Division of Genome Sciences at the NIHs National Institute of Human Genome Research, which also provided support for the study.

When the researchers looked more closely at the results, they found that eight genes had two or more damaging de novo mutations. Four of these genes, labeled RHOB, FBXO31, DHX32, and ALK, were newly implicated in CP while the other four had been identified in previous studies.

The researchers were especially surprised by the RHOB and FBXO31 results. Two cases in the study had the same spontaneous mutation in RHOB. Likewise, two other cases had the same de novo mutation in FBXO31.

The odds of this randomly happening are incredibly low. This suggests that these genes are highly linked to cerebral palsy, said Dr. Jin.

The researchers also looked at the genes behind other brain development disorders and found that about 28% of the cerebral palsy genes identified in this study have been linked to intellectual disability, 11% to epilepsy and 6.3% to autism spectrum disorders. In contrast, the researchers found no significant overlap between cerebral palsy genes and those involved with the neurodegenerative disorder Alzheimers disease which attacks the brain later in life.

Our results support the idea that cerebral palsy is not one narrow disease but a spectrum of overlapping neurodevelopmental problems, said Dr. Lewis.

Further analysis of the results suggested that many of the genes they found in this study, including six of the eight genes that had two or more de novo mutations, control the wiring of neural circuits during early development. Specifically, these genes are known to be involved in either the construction of protein scaffolds that line the perimeters of neural circuits or in the growth and extension of neurons as they wire up.

Experiments on fruit flies, formally known as Drosophila melanogaster, supported this idea. To do this, the researchers mutated fly versions of the wiring genes they identified in the cerebral palsy patients. They found that mutations in 71% of these genes caused flies to have problems with movement, including walking, turning, and balancing. The results suggested that these genes play a critical role in movement. They estimated that there was only a 3% chance these problems would happen if they had blindly mutated any gene in the fly genome.

Treatments for cerebral palsy patients have not changed for decades, said Dr. Kruer. In the future, we plan to explore how these results can be used to change that.

These studies were supported by the NIH (NS106298, NS091299, HG006504, HD050846, HL143036), the Cerebral Palsy Alliance Research Foundation, the Doris Duke Charitable Foundation (CSDA 2014112), the Scott Family Foundation, Cure CP, the National Health and Medical Research Council (Australia; grant 1099163), The Tenix Foundation, the National Natural Science Foundation of China (U1604165), Henan Key Research Program of China (171100310200), VINNOVA (Sweden's Innovation Agency; 2015-04780), the James Hudson Brown-Alexander Brown Coxe Postdoctoral Fellowship at the Yale University School of Medicine, and the American Heart Association (18POST34060008).

https://www.ninds.nih.govis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Jin, S.C., Lewis, S.A.; et al., Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nature Genetics, September 29, 2020 DOI: 10.1038/s41588-020-0695-1

###

Read the rest here:
About 14% of cerebral palsy cases may be tied to brain wiring genes - National Institutes of Health

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The GlobalTissue Banking Market, by Product (Media and Consumables, and Equipment), by Tissue (Bone, Brain & Spinal Cord, Cornea, Heart Valves, Skin, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)was valued atUS$ 1.04 billionin 2017 and is estimated to exhibit a CAGR of 10.8%during the forecast period (2018-2026),as highlighted in a new report published by Coherent Market Insights.

Transplantation is a complex area of medicine, where organs or tissues are transplanted from one person to another. Human cells and tissue transplantation are mainly performed for saving lives and/or to restore essential functions. For instance, a corneal graft can restore sight in corneal blindness, and transplantation of a human heart valve can save lives even of pediatric patients.

Moreover, government plays an important role in tissue banking establishments and management, which is expected to drive the market growth over the forecast period. For instance, in 2013, three institutes at the National Institute of Health, including the National Institute of Mental Health (NIMH), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Child Health and Human Development (NICHD) launched a joint initiative NeuroBioBank in the U.S. It links together six large organ and tissue repositories through a common web portal.

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/tissue-banking-market-2600

Key players in tissue banking market are proactively working towards the research and development of new opportunities. For instance, in October 2018, MTF Biologics announced the formation of a new tissue recovery relationship with Regenerative Biologics, Inc. The organizations will seek to provide expanded birth-tissue donation opportunities for expectant mothers and their families and enhance patients access to high-quality placental tissues for wound care applications.

Similarly, in 2017, Natera, a leader in genetic testing launched Evercord, a new offering that enables expectant parents to collect, store, and potentially retrieve their newborns cord, blood, and tissue for therapeutic use in transplantation and regenerative medicine applications.

Browse 38 Market Data Tables and 27 Figures spread through 152 Pages and in-depth TOC on Tissue Banking Market, by Product (Media and Consumables, and Equipment), by Tissue (Bone, Brain & Spinal Cord, Cornea, Heart Valves, Skin, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Global Forecast to 2026

To know the latest trends and insights related to tissue banking market press release, click the link below: https://www.coherentmarketinsights.com/press-release/tissue-banking-market-to-surpass-us-25-billion-by-2026-1378

Key Takeaways of the Tissue Banking Market:

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Originally posted here:
Tissue Banking Market To Find Better Growth with US$ 2.5 Billion By 2026 | CAGR: 10.8%: Coherent Mar - PharmiWeb.com

Prevention Efforts Prove Critical With Heightened Risk Of Legionella In School Water Systems | 2020-09-28 | ACHR News This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more. This Website Uses CookiesBy closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.

See the rest here:
Prevention Efforts Prove Critical With Heightened Risk Of Legionella In School Water Systems - ACHR NEWS

Weakness on one side of the body, slurred speech, facial drooping, inability to find or understand words; these are symptoms of a stroke which are typically sudden in onset. The symptoms can be subtle, or they can be severe. Regardless, rapid diagnosis and treatment is the key to recovery.

Not long ago, not much could have been done for someone as they were having a stroke. Often, we could only wait and see how the patient recovered with rehabilitation. For years, prevention was the only tool we had to combat initial and recurring strokes. Preventative measures such as blood pressure control, aspirin or other blood thinners, cholesterol control, and of course, a healthy diet and exercise remain especially important today. Thankfully, we now have a few more options.

Clot-busting medications have been a great advancement in the treatment of strokes since the mid-1990s. If administered soon enough, sometimes these clot-busting medications can work to break up a clot that is blocking blood flow in an area of the brain thus restoring circulation. This can help to preserve or at least minimize the area of the brain that would be permanently damaged.

There are risks to these meds, such as bleeding, but the chance of improving the outcome usually justifies their use. To minimize risks, the clot-busting medication must be initiated within three to four- and one-half hours following the onset of symptoms. Physicians also consider other criteria before treating with clot-busting meds, including the patients medical history, blood test results, and they must rule out a hemorrhagic stroke using CT imaging of the brain. A hemorrhagic stroke is when damage is done by a ruptured blood vessel rather than from blockage.

More recently, technological developments have changed the emergent care offered for very severe strokes. It is now possible to manually restore blood flow to the brain using minimally invasive surgery. A surgeon inserts a system of catheters and wires into an artery in the arm or groin, advances this system up through the neck and into the brain. Then, at the location of the blood vessel blockage, the blood clot is removed and the circulation to the affected area is restored.

Highly specialized, this new procedure seems almost miraculous. It has been referred to as the Lazarus procedure as it literally brings people back to life and sometimes immediate improvement is noted as soon as during the procedure.

The keys are recognition and time. Know the signs and get help quickly. Think of the acronym FAST: Face drooping? Arm weakness? Speech difficulty? Time to call 9-1-1.

Andrew Ellsworth, M.D. is part of The Prairie Doc team of physicians and currently practices family medicine in Brookings, South Dakota. For more information, visit http://www.prairiedoc.org.

Here is the original post:
Advances in the treatment of stroke | Columnists | rocketminer.com - Daily Rocket Miner

Where has Victoria Beckham gone to recover after her spring/summer 2021 presentation in London? A luxurious house of wellbeing in Germanys Baden-Baden, of course. Villa Stphanie Baden-Baden is the exclusive hotel, spa and medical centre that Beckham swears by for its restorative mind and body detox treatments.

Postcard from our wellness week in Germany! the fashion designer wrote on Instagram on 26 September, posting a snap of herself and David staring out across a verdant landscape. Her stories showed off more green scenes from hiking with her husband of 21 years in the peaceful Black Forest, ultra-healthy broccoli-packed meals and couple shots in front of amazing sunsets.

She also took time to thank Dr Harry Koenig, a holistic naturopath and expert in preventative medicine, who owns a private clinic in Baden-Baden. Clinics like these take ones lifestyle into account from diet to stress levels and prescribe various holistic therapies off the back of that information, whether thats acupuncture or herbal tinctures.

Beckham previously told British Vogue that her first trip to Villa Stphanie wasnt initially what she expected she felt emotional and weepy since it was her first solo trip without David or her children. But, after daily meditating, hiking and bike riding, she started to enjoy just being kind and looking after me. Now, with David at her side, the exclusive wellness destination has obviously worked its magic on her once again.

More from British Vogue:

The rest is here:
For Victoria Beckham, Fashion Week Recovery Begins At This Exclusive German Spa - British Vogue

Financially solid, younger new members, two new plans, virtual healthcare and a renewed focus on Managed Care for chronic diseases are just a few of the insights from the Bonitas 2021 product launch.

Lee Callakoppen, Principal Officer of Bonitas Medical Fund announced an unprecedented 0% increase on its BonFit Select plan and a weighted increase of 4.6% across all plans. The highest increase is 7.1%. Members on our growth options, which contribute to 91% of business, will only experience an increase on 3.9%. I think, looking at the pricing and the benefit richness we offer in comparison to the market, the changes for 2021 will be well received.

He says, The guidelines received from the Council for Medical Schemes (CMS), clearly highlighted that medical schemes should limit contribution increases as far as possible. We crunched numbers and worked tirelessly to find the sweet-spot between sustainability and ensuring affordability. Not an easy task, especially in a weakened economy. We took a responsible stance, with a long-term view, to ensure that our members wouldnt have to pay the price of a low increase for 2021 in the coming years. One of our core considerations was finding ways to ensure members could get access to full healthcare cover and avoid out-of-pocket expenses and co-payments.

Pricing and technology

Seven of our current options are priced between R1500 and R3000 which is where the medical scheme market is experiencing growth currently. Member behaviour has changed significantly and demand is for innovation, accessibility and technology. This has the benefit of attracting, a younger, target audience and driving sustainability.

We cant talk about 2020 without mentioning Covid-19. Key trends that emerged from a medical schemes perspective were:

- Changes to benefit structures and PMBs

- Lower than anticipated investment income as markets slumped

- Changes in claiming patterns in terms of seasonality and volume, due to the lockdown measures that came into effect

- And a Consumer Price Index that was lower than previous years which is expected to be at around 3.9% in 2021

In an industry like ours, its challenging to be different to innovate, disruptto be better. But not impossible. The Fund needed to make short-term decisions with the long-term view and sustainability in mind.

One of the highlights over the past few years, has been the introduction of four Efficiency Discounted Options (EDOs). Plans whereby members use network healthcare providers and pay around 15% less for the same benefits. The EDOs cover over 74,000 lives and the principal members who join are around 10 years younger than the average Bonitas member.

2021 - changes, contribution increases and enhancements

Over the past five years, we have proactively driven innovative product design, actuarial modelling and constant engagement with various stakeholders. We believe we offer the ultimate split risk solution, with a comprehensive product range and diversified membership base.

To stay at the forefront of innovation we have introduced:

Edge - a new category driven by technology, intelligence and innovation, with two plans called BonStart and BonStart Plus. These are designed for economically active singles or couples, living in the larger metros.

The plans include access to: A private hospital network and full cover for emergencies; PMB chronic medicine; excellent day-to-day benefits including unlimited GP consultations; layers of virtual care, dental and optical benefits; preventative care; wellness screenings; contraceptives and more. The cost: R1452 and R1731 respectively for the principal member.

Managed Care

One of the leading trends worldwide is the rise in non-communicable diseases, such as diabetes, high blood pressure and oncology. In fact, during this global pandemic, the impact lifestyle diseases and comorbidities had on Covid-19 patients was put in the spotlight. 20% of our members have multiple comorbidities which means, even without the pandemic, we need a stronger focus on preventing and managing lifestyle behaviours. Poor diet, smoking and lack of exercise are the three lifestyle factors that contribute to over 80% of chronic conditions.

Managed Care continues to be a focus to empower members to take charge of their health and support them along the way.

Home-based care

During Covid-19, home-based care received renewed interest and focus. This dovetails with our strategy to move more care to the home and out of hospital. As an example, post-surgery or mild pneumonia, treatment can be effectively provided at home through the assistance of nurses. Not only is home-based care a cost effective delivery of care but it also promotes healing. Studies show that patients recover faster in their comfort of their own home.

Day hospitals

We believe the use of day hospitals and clinics should be encouraged, where possible. Some procedures such as cataract surgery, circumcisions and scopes are better suited to be performed in day hospitals or clinics versus larger hospitals. There is minimum disruption to members, speedier recovery times, less risk of infection and day hospital are also a more cost effective alternative.

Technology

One of the key learnings has been adapting to a new way of working with virtual technology at the forefront. The WhatsApp channel we introduced has the most room for potential. This platform is convenient for members and allows them to manage their medical aid through live chats.

Virtual Care

There was a positive response to the launch of the new Bonitas Member Mobile App and free virtual care for all South Africans. This provided access to GP consultations for a range of conditions, including Covid-19, as well as free delivery for chronic medicine.

At the heart of the model is the GP. This aligns to our care coordination initiatives, ensuring members receive the right level of care and support in managing their conditions. It allows access to a virtual nurse, advice in an emergency, auxiliary and home- based care, ensuring members have comprehensive support for any condition, in any circumstance, through our virtual based model.

Were pleased to announce that this model is unique and will guarantee a further level of differentiation for Bonitas.

Mental health

Is fast becoming the next pandemic and is a significant Managed Care risk. Studies show that around 20 -25% of patients with pre-existing mental health issues feel they are coping badly or deteriorating due to the pandemic. We predict that depression and post-traumatic stress, which has historically been on an upward slope, will increase further in time.

We have built a resource hub on our website to help people understand the condition and steps they can take to remain mentally healthy. The app also has a screening tool to help identify warning signals of mental distress. For those who need medical treatment, the focus is on ensuring that care for the mental illness is provided effectively.

The Wellness Extender

Is one of our key benefits as it provides access to another layer of care paid from risk. In 2021 the Wellness Extender can be used to pay for up to three months subscription fees for Run/Walk for Life to help our members get healthier.

Conclusion

We are looking forward to new and innovative ways of empowering members to manage their health in 2021 and beyond. Our focus is on more primary healthcare, utilisation of preventative care benefits, digitally enabled solutions and self-help facilities for members who want access to their benefits 24/7. Our goal is to improve integration of care, enable more access to out-of-hospital services, clinical information and benefits via various solutions.

We have listened to our members needs and will be rolling out various tools and services to provide additional clinical support, an easier claims process and access to various helpful tools on our website. We are a medical aid for South Africa and our commitment of providing quality care, connecting with our customers and driving innovation is unwavering.

Originally posted here:
Bonitas announces the lowest increase in 10 years - from 0% - Bizcommunity.com

Two community health centers on the Big Island will receive additional federal funding to support efforts in mitigating disparities among Pacific Islanders affected by COVID-19.

The University of Hawaii (UH) at Manoa will receive $3.4 million in federal funding from the Department of Health and Human Services to support efforts to expand testing and outreach programs to Waimanalo Health Center on Oahu; the Bay Clinic Inc. and Hmkua-Kohala Health Center on Hawaii Island; and the Molokai Community Health Center.

We must use every public health intervention available to prevent the spread of COVID-19 in our vulnerable populations, and especially to reduce the disparities weve seen in the Pacific Islander community, said US Sen. Brian Schatz (D-Hawaii). By expanding access to COVID-19 testing and teaching preventative practices to students in rural areas, this grant will help us keep more Hawaii families safe. Im proud that UH is leading this effort to bring additional resources to areas that need it most.

The program is already successfully implemented at Waianae Coast Comprehensive Health Center on Oahu. The additional funds will be used by UH to increase COVID-19 testing and disseminate COVID-19 educational curriculum to schools in rural and underserved communities in effort to reach Hawaiis vulnerable populations, including Native Hawaiians and other Pacific Islanders.

Hmkua-Kohala Health Center

At the same time, UH will disseminate COVID-19 educational curriculum to community schools to empower students and families to implement preventative practices, encourage testing, and help reduce infections.

We are pleased to address an issue of such great importance to our state and one which disproportionately impacts Hawaiis vulnerable populations. This partnership with community health centers and scientists across our great university represents a great opportunity to proactively and uniquely contribute to the health of Hawaii, said Jerris Hedges, Dean of the John A. Burns School of Medicine, and Dr. Noreen Mokuau, former Dean of the Myron B. Thompson School of Social Work.

See the original post here:
2 Big Island Clinics to Receive Federal Funding to Expand COVID Testing, Education - Big Island Now

Tuesday, 29 September 2020, 6:04 amPress Release: The Heart Foundation

TheHeart Foundation today announced $4.2 million dollars offunding for heart research and specialist training for NewZealand cardiologists, bringing the total awarded by thecharity since its formation in 1968, to more than $78million dollars.

We have a long and proud record ofresearch investment, which has improved the heart health ofall New Zealanders for more than 50 years, but we still havemuch more work to do, says Heart Foundation MedicalDirector, Dr Gerry Devlin.

Heart disease is NewZealands single biggest killer. With our ongoingcommitment to supporting research, we can keep saving livesand improve the quality of life for the 170,000 NewZealanders living with heart disease.

This year theHeartFoundation has awarded research grants across thebench-to-bedside spectrum, including new treatments,structural interventions and prevention.

The HeartFoundation is supporting so much exciting research in 2020.Research that will make a real difference to so manyKiwis, says Dr Devlin.

The Heart Foundation isproud to support leaders across all areas of medicine inAotearoa, such as neonatal paediatrician Dr Sarah Harris,whose work will investigate the link between prematurebabies and heart disease.

Emerging evidence showsadults who were born prematurely, and mothers who give birthto a premature baby, are at increased risk of cardiovasculardisease but neither are included in our national guidelinesfor cardiovascular risk screening, says DrHarris.

The birth of a premature baby may be anopportunity to review cardiovascular risk for both motherand baby and to initiate an earlier programme of risksurveillance, health education and preventative care thatcould have intergenerationalbenefit.

This year a new grant tosupport nurses in the field of cardiology has also beenintroduced.

The new Nurse PractitionerTraining Fellowship in Cardiovascular Disease, has beenawarded to Edel Schick, enabling her to develop patienteducation and focus on disease prevention in thecommunity.

The Heart Foundation is especially proud tomake these announcements on WorldHeart Day and, with the support of SkyCity, to be ableto light Aucklands Sky Tower red this evening, joiningwith our global heart community and paying tribute to allwho have lost a loved one to heart disease.

Wevecome a long way, with a 75 per cent reduction in deaths fromheart disease since we started our work. But heart diseasestill claims more than 6,000 lives in New Zealand each yearand one preventable death is one too many, says DrDevlin.

The 2020 awards include 6 ProjectGrants, 2 Overseas Training and Research Fellowships, 6Research Fellowships, 2 Mori Cardiovascular ResearchFellowships, 4 Small Project Grants and 3 SummerStudentships.

* Heart disease is New Zealands singlebiggest killer, claiming the lives of more than 6,700 NewZealanders every year thats one person every 90minutes.

* More than 170,000 New Zealanders arecurrently living with heart disease.

* The HeartFoundation funds cutting-edge research and specialisttraining for cardiologists, while our education andprevention programmes address heart disease head-on in thecommunity.

* The Heart Foundation is NewZealands heart charity that is leading the fight againstheart disease.

* As a charity we rely heavily onthe generosity of everyday Kiwis to support our life-savingwork.

Scoop Media

Become a member Find out more

Original post:
Heart Foundation Research Grants Top $78 Million On World Heart Day - Scoop.co.nz

FULL INTERVIEW: Staying safe at the polls during the presidential election

A physician with the Infectious Diseases Society of America discusses how to safely vote during the 2020 election.

LOS ANGELES - The United States is still in a pandemic as the 2020 presidential election draws near, leaving many worried about voting safely during the COVID-19 crisis.

Many public health experts agree that voting by mail is the safest method to avoid the risk of transmission of COVID-19, but how can people who want to vote in person stay safe?

Dr. Krutika Kuppalli, a physician with the Infectious Diseases Society of America (IDSA) and an assistant professor of medicine in the division of infectious diseases at the Medical University of South Carolina, said each state has its own rules and regulations regarding the handling of polling places on election day. IDSA is advocating for a variety of measures be put into place to reduce the risk of coronavirus transmission.

Hispanic voters go to the polls for early voting at the Miami-Dade Government Center on October 21, 2004 in Miami, Florida

For people who cant vote [mail-in], theres certain steps that they can take to mediate the risk of getting coronavirus, Kuppalli said.

Wear a mask and disinfect

Kuppalli suggests bringing personal preventative items with you to your polling place, such as your own mask and hand sanitizer.

Kuppalli said this will not only help reduce the risk of obtaining or transmitting COVID-19, but it will let people around you know that you are doing the best that you can to protect yourself and others.

IDSA is also advocating for election sites to have items such as masks and hand sanitizer available, and is urging that routine disinfection be done at polling places.

Maintain a good physical distance

We recommend that people stay at least six feet apart, Kuppalli said. Weve [IDSA] also recommended that, one of the things that election officials and voting places to do is to mark that distance, so people know they are maintaining that distance.

RELATED:Mail-in and absentee ballots: How to ensure yours is properly filled out and doesnt get rejected

Fill out a sample ballot before arriving

Kuppalli recommended filling out a sample ballot before arriving at your polling destination.

By knowing who you are voting for ahead of time, you can be quicker and more efficient at your polling site, Kuppalli added.

However long we are exposed to the coronavirus, that increases our risks of getting it. So, the less time we have to wait in line at the polls, that will be hugely important, Kuppalli added.

Head to the polls at off-peak hours

Kuppalli suggested heading to the polls when there are less people.

Weve recommended that people try to show up early on election day, and if possible to show up at off peak voting times so that might mean early in the morning, Kuppalli noted.

She also recommended going alone to vote if that is possible the less people gathered at the polls, the safer the process will be.

In addition, IDSA is advocating for more polling places, which would reduce the density of people at each location. Then there wouldnt be as many voters at one particular site and people would not need to wait in as long of lines.

Try to reduce your risk of transmission leading up to the 2020 election

Continuing to follow CDC guidelines, such as wearing a mask, washing hands and maintaining social distance leading up to the election, will help reduce potential spread of the coronavirus, Kuppalli said.

RELATED:Election officials, experts and USPS urging voters not to wait until state deadlines to mail in ballots

Kuppalli said IDSA is also advocating for free testing after the election.

Were recommending that free testing be available for people in the aftermath of the election, because we want to make sure that people who may be exposed be able to get tested. Thats all very important, Kuppalli said.

What if I have been exposed to COVID-19?

IDSA has advocated that polling places have contingency plans set up, because as much as we plan people may be coming to the polling sites sick, Kuppalli said.

Here are some options for those who find themselves wary of the U.S. Postal Services ability to deliver their ballot on time.

IDSA advocated that all polling places have contingency plans in place such as curbside voting, which would decrease the risk of exposure for both voters and poll workers.

Kuppalli suggested checking in with your local election officials to find of your countys contingency plan, because every locality will have different plans in order.

Is it safe to volunteer to be a poll worker?

This is the year that we need everybody who can be a poll worker to please come out and volunteer to be a poll worker, Kuppalli said.

IDSA is advocating that people in younger age groups, who have less risk of serious illness, choose to volunteer on Election Day.

RELATED:USPS launches website providing resources and information on mail-in ballots ahead of 2020 election

If you have questions about your risk in being a poll worker, Kuppalli said you should check in with your health care provider.

Utilize mail-in voting if possible

Theres no such thing as zero risk, Kuppalli said. Theyre all things that we can do to mitigate our risk.

The ongoing COVID-19 pandemic is pushing states to ramp up their mail-in voting efforts for the 2020 election, but the rules vary from state to state.

Kuppalli said that mail-in voting is still the safest way to vote in terms of reducing risk for coronavirus transmission.

If people can do mail-in voting, then they should. Its the safest way from a COVID transmission standpoint to decrease their risk of getting COVID, Kuppalli said.

Read more from the original source:
Election 2020: How to protect yourself at the polls amid COVID-19 pandemic - FOX 10 News Phoenix

FRANKFORT, Ky. (WTVQ) Summit Biosciences Inc., a Lexington-based pharmaceutical company focused on nasal spray medicines, is expanding its operation at the University of Kentucky Coldstream Research Campus with a more than $19 million investment expected to create up to 78 full-time jobs.

The project has grown significantly since it originally was announced in 2016 as a $7.9 million project that would create 21 jobs.

We need companies like Summit Biosciences more than ever, and I could not be happier to see its tremendous growth in Lexington, Gov. Andy Beshear said. This company has represented what it means to be part of Team Kentucky during this pandemic, donating personal protective equipment to the local community and working on an urgently needed treatment for coronavirus. Summit Biosciences is a company with a bright future in Kentucky.

The expansion, which is nearing completion, brings the companys footprint to 44,000 square feet with increased manufacturing, laboratory and warehouse space.

The additional space will support clinical and commercial production of several new nasal spray medicines, including one for COVID-19.

In May, Atossa Therapeutics Inc., a Seattle-based pharmaceutical company, awarded Summit a contract to accelerate the development of a nasal spray medicine for preventing and/or mitigating a COVID-19 infection.

The proposed product is being developed as an at-home, easy-to-administer preventative or treatment option for patients and is among a very limited number of medicines or vaccines that will rely on intranasal delivery.

Atossa selected Summit for its specialized capabilities, industrial-scale infrastructure and proven track record in nasal spray medicines.

We are excited and honored to have been entrusted by Atossa Therapeutics to aid in the development of a product that could potentially be used in the global fight against the coronavirus, said Greg Plucinski, president and COO of Summit. Our dedicated, high-performing team has taken this immense responsibility and worked extremely hard to deliver products for the start of human clinical studies in record time.

Summit was founded in Lexington in 2009 by Edwin Cohen. The company develops and manufactures prescription nasal sprays for other pharmaceutical companies to commercialize and distribute throughout the U.S. and Europe.

Having grown steadily since its inception, Summits expansion has ramped up in recent years. Since December 2016, its staff has grown from 45 to 125 employees.

State Rep. George Brown, of Lexington, expressed gratitude for Summits work during a time of great need.

This announcement is both great news for our community and for our frontline role in trying to prevent the spread of COVID-19, Rep. Brown said. I want to thank Summit Biosciences for investing further here in Lexington and creating these much-needed new jobs, and I also appreciate the hard work by our local and state officials to help make this possible.Heres hoping this work bears positive fruit and quickly.

Lexington Mayor Linda Gorton noted the companys local roots and steady growth.

If you want to understand the strength of our economy, take a look at Summit Biosciences, Mayor Gorton said. The story starts with University of Kentucky brainpower in pharmaceuticals. Next, an investment from the citys Jobs Fund and from the state to get this UK start-up off the ground.

By 2016, the company employs 45; then 100 in 2018; and now 125. Similarly, Summits facility has continued to expand, from 7,850 square feet in 2018 to 44,000 square feet today. Summits success story is also our communitys success story in growing good jobs. I recently visited their offices in Coldstream Research Campus. Summit Biosciences, congratulations! Gorton continued.

Bob Quick, president and CEO of Commerce Lexington Inc., said the company has been an ideal community partner.

To encourage the investment and job growth in the community, the Kentucky Economic Development Finance Authority (KEDFA) in July gave final approval to a modified 10-year incentive agreement with the company under the Kentucky Business Investment program. The performance-based agreement can provide up to $1.5 million in tax incentives based on the companys investment of $19 million and annual targets of:

By meeting its annual targets over the agreement term, the company can be eligible to keep a portion of the new tax revenue it generates. The company may claim eligible incentives against its income tax liability and/or wage assessments.

In addition, Summit can receive resources from the Kentucky Skills Network. Through the Kentucky Skills Network, companies can receive no-cost recruitment and job placement services, reduced-cost customized training and job training incentives.

For more information on Summit Biosciences visitSummitBiosciences.com. For a video message from Summit Bioscience,click here.

See the rest here:
Summit Biosciences to create 78 full-time jobs in Lexington - ABC 36 News - WTVQ

More than a high BMI, an obese heart is a silent risk: New research shows that fat tissue around the heart releases molecules that alter heart rhythm, identifying potential new targets for preventative therapies for heart disease By Professor Lea Delbridge, University of Melbourne and Dr James Bell, La Trobe University and University of Melbourne.

More than two thirds of Australians are now overweight or obese.

More than just a statistic, this figure is concerning because obesity is associated with a number of long-term health issues including diabetes, cardiovascular disease, some cancers, musculoskeletal disease, disability and has recently emerged as a risk factor in COVID-19 morbidity.

Of these, heart disease is Australias biggest killer. And irregular heart rhythms, known as atrial fibrillation (AF), are an early phase of heart disease, which can lead to stroke, heart failure and, eventually, death.

AF is also associated with accelerated dementia and depression.

In Australia, one in 11 deaths are linked to atrial fibrillation with an economic cost of more than $A1.25 billion per year. Described as a silent killer, many people with AF have no symptoms and it is often difficult to diagnose.

It has been known for some time that obesity is a critical risk factor for AF. Each unit increase in body mass index (BMI) increases AF risk by four to five per cent.

So, developing new preventative therapies for treating AF is crucial to reducing the public health and economic burden of this disease.

Our latest study published in the Journal of the American College of Cardiology has highlighted that the build-up of fat around the heart is especially dangerous for heart health showing a link between the fat deposit on the surface of the heart muscle with atrial fibrillation.

The Framingham Heart Study first identified an important, but poorly understood link between accumulation of fat around the heart and the risk of the most common form of irregular heart rhythms atrial fibrillation.

This then culminated in a new collaboration, between pre-clinical researchers and clinical cardiologists at the University of Melbourne and Melbourne Biomedical Precinct.

Our group has been researching the role of cardiac adipose (fat tissue) in regulating heart muscle contraction and heart pump function for a number of years.

And our partners, Drs Jon Kalman and Chrishan Nalliahs team from the Department of Medicine at the Royal Melbourne Hospital, have been investigating the effects of patient obesity on the electrical abnormalities which provoke AF.

During the project, while patients were still undergoing surgery, we could rush heart tissue fragments (removed as part of the surgical process) into the research lab and work on them immediately.

The most common irregular rhythms of the upper chambers of the heart atrial fibrillation are more prevalent in aged and obese populations. One in three people will develop AF beyond the age of 55 and the risk accelerates with increasing age.

People are often unaware they have AF and the first sign could be tragic: a stroke due to blood clot traveling to the brain or the danger of a sudden blackout with dire consequences.

Silent progression to heart failure is common, with AF only detected when the symptoms of heart failure emerge.

Changes in heart rhythms

Most people dont realise that there is a lot of fat adipose tissue around the heart muscle. In extreme cases the amount of fat has been found to be up to 50 per cent of the entire heart weight.

Our research has shown that the adipose tissue around the heart produces biochemical factors which changes the way electrical signals move through the heart muscle tissue to generate the heartbeat.

The cell-to-cell communication is disrupted, and the transfer of the electrical signal between cells (which creates the heart beat) is delayed. These factors have a potentially major role in causing disruption of electrical activity which underlies atrial fibrillation.

And although BMI increases the risk of AF, it is the cardiac adipose burden (and not BMI) that is most important in electrical and structural disruption.

There are no general screening processes, no preventative treatments and AF and AF complications are associated with hospitalisation rates of up to 40 per cent.

It is also likely that AF is under-diagnosed in women.

Men often undergo cardiac surgery to unblock coronary arteries where AF is then often detected. Heart disease with major artery involvement is much less common in women, so AF often remains undetected until the disease is dangerously advanced.

Potential new treatments

Understanding the basic causes, early intervention and developing new preventative therapies is crucial.

Current treatments for those diagnosed with AF are limited and lack effectiveness. They are designed to abolish the irregular heart rhythms without addressing the underlying cellular causes.

Drug therapies can actually make arrhythmias worse and the common atrial ablation catheter procedure only works for a limited time and repeat procedures are common.

By showing that the fat around the heart drives these rhythm irregularities, our study identifies potential new targets for developing preventative therapies that may reduce the catastrophic health consequences.

Our research suggests that more proactive management to measure the heart adipose load should be undertaken as part of a risk assessment.

It also raises the possibility that a surgical approach to reduce cardiac adipose (fat) tissue could be an intervention to consider in future and identifies molecular signalling which may potentially pave the way for targeted drug treatment.

A link to living in a time of Covid?

Obesity has emerged as a major risk factor for morbidity in COVID-19 patients, with cardiovascular complications a major underlying cause of death.

The causes underlying this are poorly understood. It is possible that the fat surrounding the heart is implicated.

Our study shows that factors released from the heart can have potentially catastrophic effects on how the heart muscle functions but the extent to which this underlies the cardiovascular component of COVID-19 mortality or morbidity has yet to be further explored.

Research support for this work was provided by the National Health and Medical Research Council.

This article first appeared in Pursuit.

More here:
An obese heart is a silent risk - The Hippocratic Post

This minutely analyzed and systematically articulated business intelligence report based on global Stem Cell Therapy market is poised to enable seamless navigation to all crucial market participants and other report readers and stakeholders interested to carving a new growth route to offset multiple challenges in global Stem Cell Therapy market. Besides dedicating a significant crux of the report in re-imaging and re-assessing conventional marketing strategies, the report is designed to push the boundaries in unravelling new and improved damage control practices to align with growth needs and manufacturer preferences.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, and Chart): https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=Pallavi

Global Stem Cell Therapy market research report presentation demonstrates and presents an easily understandable market depiction, lending crucial insights on market size, market share as well as latest market developments and notable trends that collectively harness growth in the global Stem Cell Therapy market.

Scope of the ReportThis aforesaid Stem Cell Therapy market has noted a growth estimate of xx million US dollars in 2020 and is also likely to show favorable growth worth xx million US dollars through the forecast tenancy until 2025, clocking at an robust CAGR of xx% through the forecast period, 2020-25.

The report has included significant details about various facets covering manufacturer activities to offset the challenges prevalent during COVID-19.

The report in the following sections, emphasizes details on various market players, stakeholders, and participants. Details on upstream and downstream developments, production and consumption patterns are also addressed in the report to influence holistic and balanced growth in the global Stem Cell Therapy market.

ACCESS FULL REPORT @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=Pallavi

Stem Cell Therapy Market SegmentationType Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Regional Analysis: Global Stem Cell Therapy MarketSegment Assessment: Global Stem Cell Therapy Market1. The report in its subsequent sections critically examines the crucial possibilities teeming in the global Stem Cell Therapy market and stresses on the tangibility of segments in enticing a favorable growth journey.2. Besides segregating the market in accordance with broad categories and segments, the report makes accurate deductions in isolating the segment responsible for steady and balance growth trail.3. With such decisive information outlined in the report, report readers can well assess and propagate competent growth strategies to ensure healthy investment returns.4. Further, details on regional as well as country-wise developments are also portrayed in the report with specific references also of country wise developments that tend to push million dollar growth opportunities.5. The report also further answers key questions about the raw material and manufacturing equipment incorporated by leading players and the manufacturing process incorporation

Vendor Profiling: Global Stem Cell Therapy Market1. The report in its subsequent sections unfurls crucial inputs pertaining to the chief competitors in the Stem Cell Therapy market. Additional information related to other contributors and notable key players and contributors with reference to local and regional dominance also find requisite mention in the report.2. Each of the players mentioned in the report have been thorough scrutinized on the basis of their company and product portfolios to make logical deductions related to strategic planning and winning business decisions.3. All the listed players mentioned in the report has been subject to thorough assessment and evaluation process to unfurl valuable insights on company profiles, their positioning in the competitive graph, portfolio diversifications as well as notable business moves that have proved success and steady revenue generation.

Ask our Expert if You Have a Query at: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=Pallavi

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

More:
Stem Cell Therapy Market 2020 by Top Key Players, Product Type, End-user Applications, Region and Forecast to 2025 - The Daily Chronicle

Fort Collins, Colorado The Stem Cell Therapy Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The Stem Cell Therapy Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the Stem Cell Therapy Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global Stem Cell TherapyMarketwas valued at 117.66 million in 2019 and is projected to reach USD255.37 million by 2027, growing at a CAGR of 10.97% from 2020 to 2027.

Industry Stem Cell Therapy Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=33553

The report provides comprehensive data on the Stem Cell Therapy market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Stem Cell Therapy Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Stem Cell Therapy market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=33553

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Stem Cell Therapy Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-therapy-market/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Visit link:
Stem Cell Therapy Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle

New York City, United States The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

About- Persistence Market Research (Healthcare)

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes

More:
The Canine Stem Cell Therapy Market To Go Strong With 4.2% CAGR Between 2026 - Crypto Daily